|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
4.770 USD |
+3.02% | +12.24% | -41.26% | |
April 16, 2025 at 08:22 am EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Phathom Pharmaceuticals Appoints Ted Schroeder To Its Board Of Directors |
08:22am |
RE |
|
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
Apr. 01 |
RE |
|
Phathom Pharmaceuticals Names Steven Basta CEO |
Apr. 01 |
MT |
|
Phathom Pharmaceuticals Announces Leadership Succession |
Apr. 01 |
RE |
|
Phathom Pharmaceuticals, Inc. Announces CEO Changes |
Apr. 01 |
CI |
|
Phathom Pharmaceuticals, Inc. Announces Management Changes, Effective April 1, 2025 |
Apr. 01 |
CI |
|
Phathom Pharmaceuticals, Inc.(NasdaqGS:PHAT) dropped from S&P Pharmaceuticals Select Industry Index |
Mar. 23 |
CI |
|
Jefferies Cuts Price Target on Phathom Pharmaceuticals to $13 From $17, Maintains Buy Rating |
Mar. 19 |
MT |
|
Phathom Pharmaceuticals, Inc., Q4 2024 Earnings Call, Mar 06, 2025 |
Mar. 06 |
|
|
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Mar. 06 |
CI |
|
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 |
Mar. 06 |
CI |
|
Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals With Overweight Rating, $23 Price Target |
Feb. 14 |
MT |
|
Phathom Pharmaceuticals, Inc. Presents at Guggenheim SMID Cap Biotech Conference, Feb-06-2025 10:00 AM |
Feb. 06 |
|
|
Phathom Pharmaceuticals Files US FDA Petition to Seek Voquezna Exclusivity Period |
Dec. 11 |
MT |
|
Phathom Pharmaceuticals, Inc. Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for Vquezna®? Tablets |
Dec. 11 |
CI |
|
Phathom Pharmaceuticals, Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-03-2024 02:10 PM |
Dec. 03 |
|
|
Phathom Pharmaceuticals, Inc. Presents at Stifel 2024 Healthcare Conference, Nov-18-2024 01:15 PM |
Nov. 18 |
|
|
Phathom Pharmaceuticals Shares Fall After Q3 Loss Widens |
Nov. 07 |
MT |
|
Earnings Flash (PHAT) PHATHOM PHARMACEUTICALS Posts Q3 Loss $-1.05 Per Share |
Nov. 07 |
MT |
|
Phathom Pharmaceuticals, Inc., Q3 2024 Earnings Call, Nov 07, 2024 |
Nov. 07 |
|
|
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 07 |
CI |
|
Phathom Pharmaceuticals, Inc. to Present Data from Multiple Investigational Studies for its First-In-Class Treatment VOQUEZNA®? Tablets at the American College of Gastroenterology 2024 Annual Scientific Meeting |
24-10-27 |
CI |
|
Certain Common Stock of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-OCT-2024. |
24-10-17 |
CI |
|
Phathom Pharmaceuticals, Inc.(NasdaqGS:PHAT) added to S&P Pharmaceuticals Select Industry Index |
24-09-22 |
CI |
|
Phathom Pharmaceuticals Prices Underwritten Offering of Shares and Warrants |
24-08-19 |
MT |
PHAT: Dynamic Chart
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
More about the company
Buy
Average target price
20.88USD
Spread / Average Target
+337.63%
Consensus
